Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.943
-0.037 (-3.76%)
At close: Feb 21, 2025, 4:00 PM
0.950
+0.007 (0.73%)
After-hours: Feb 21, 2025, 7:30 PM EST
Palisade Bio Employees
Palisade Bio had 9 employees as of December 31, 2023. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,562,778
Market Cap
2.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
PALI News
- 2 days ago - Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - GlobeNewsWire
- 3 days ago - Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 12 days ago - Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
- 24 days ago - Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress - GlobeNewsWire
- 7 weeks ago - Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - What's Going On With Palisade Bio Stock On Thursday? - Benzinga